I am a medical oncologist who has clinical and research expertise in genitourinary medical oncology as well as clinical trials. My clinical practice is at Boston Medical Center and includes adult patients with cancers of the prostate, kidney, bladder, testicles and penis, as well as other solid cancers. My treatment expertise is in hormonal agents, chemotherapy, immunotherapy, targeted therapies, radioactive pharmaceuticals, bone targeted therapies, supportive and palliative care. I am also an educator in the Boston University School of Medicine and Boston Medical Center Hematology and Oncology Fellowship Program.
- Member, BU-BMC Cancer Center, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
- University of Pennsylvania School of Medicine, MD
- University of Rochester, BA
- Published on 2/22/2020
Chua S, Qureshi MM, Boyd G, Gignac GA, Hirsch AE. Outcomes for Young Men With Localized Intermediate-Risk Prostate Cancer: An Analysis of the NCDB. Clin Genitourin Cancer. 2020 10; 18(5):e531-e542. PMID: 32220567.
- Published on 6/13/2018
Karantanos T, Karanika S, Seth B, Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol. 2019 Feb; 21(2):206-212. PMID: 29948974.
- Published on 12/13/2017
Kan CK, Qureshi MM, Gupta A, Agarwal A, Gignac GA, Bloch BN, Thoreson N, Hirsch AE. Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):181-189. PMID: 29904743.
- Published on 9/1/2016
Karantanos T, Karanika S, Gignac G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer. 2016 Sep; 23(9):691-8. PMID: 27515296.
- Published on 4/22/2015
Gunnarsson O, Basaria S, Gignac GA. Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. Cancers (Basel). 2015; 7(2):679-87. PMID: 25913100.
- Published on 5/20/2011
Gunnarsson O, Basaria S, Gignac G. The prevalence of metabolic risk factors in black men with prostate cancer undergoing consideration for androgen-deprivation therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):e15082. PMID: 28020432.
- Published on 4/8/2011
Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25. PMID: 24673925.
- Published on 4/1/2011
Ariel E. Hirsch, John J. Cuaron, Milos J. Janicek, Kit Mui, Richard J. Lee, David S. Wang, Richard K. Babayan, Ann C. Zumwalt, Gretchen A. Gignac, Wen Tao, Alexander Ozonoff, Anthony L. Zietman et al. . Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Practical Radiation Oncology. 2011; 1(2):115-125.
- Published on 5/20/2009
Chi D, Hirsch AE, Gignac GA. Biochemical failure after radiation therapy for prostate cancer: Racial differences. J Clin Oncol. 2009 May 20; 27(15_suppl):e16071. PMID: 27963037.
- Published on 5/20/2009
Dickstein RJ, Kreshover JE, Milose JC, Gignac GA. Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era. J Clin Oncol. 2009 May 20; 27(15_suppl):e16159. PMID: 27963401.
View 6 more publications: View full profile at BUMC